BACKGROUND Here we describe the consensus guideline methodology, summarise the
evidence-based recommendations we provided to the World Health Organisation (WHO) for …

Metformin is an effective agent with a good safety profile that is widely used as a first-line
treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy …

Methods The original intervention (mean treatment duration 7.8 years) involved 160 patients
with type 2 diabetes and microalbuminuria who were randomly assigned (using sealed …

Aim To assess the comparative efficacy and safety of sodium‐glucose co‐transporter‐2
(SGLT2) inhibitors in adults with type 2 diabetes. Methods We electronically searched …

The current classification system presents challenges to the diagnosis and treatment of
patients with diabetes mellitus (DM), in part due to its conflicting and confounding definitions …

Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent
does not generally provide durable glycaemic control over the long term. Sulphonylurea …

Metformin is a first line oral anti-diabetic agent that has been used clinically to treat patients
with type 2 diabetes for over 60 years. Due to its efficacy in therapy and affordable price …

Background—We sought to determine the concordance between the accumulating evidence
about the impact of tight versus less tight glycemic control in patients with type 2 diabetes …

Liraglutide is an acylated glucagon-like peptide-1 analogue with 97% amino acid homology
with native glucagon-like peptide-1 and greatly protracted action. It is widely used for the …

Aim To appraise the Diabetes Self-Management Questionnaire (DSMQ)'s measurement of
diabetes self-management as a statistical predictor of glycaemic control relative to the widely …